AIM
ICPT

Artemis Investment Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Artemis Investment Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,030
Closed -$974K – 247
2015
Q2 		$974K Buy
4,030
+2,457
+156% +$654K 0.03% 185
2015
Q1 		$444K Buy
+1,573
New +$341K 0.02% 220

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Artemis Investment Management's ICPT Position: Q3 2015 in Review

Artemis Investment Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2015, closing a stake of 4,030 shares — an estimated $974K sold.

Artemis Investment Management first reported a position in ICPT in Q1 2015 and held it in 2 quarters. The position peaked at $974K in Q2 2015. 173 funds tracked by Wall St. Rank hold ICPT as of Q3 2015.

  • Artemis Investment Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Artemis Investment Management sold 4,030 Intercept Pharmaceuticals, Inc. shares in Q3 2015, an estimated $974K.
  • Artemis Investment Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • Artemis Investment Management's Intercept Pharmaceuticals, Inc. position peaked at $974K in Q2 2015.
  • 173 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2015.

Based on Artemis Investment Management's 13F filing for Q3 2015, filed 6 Nov 2015.